In-vivo antidiabetic and antidyslipidemic effects of methanolic leaf extract of Combretum indicum in the streptozotocin-induced diabetic rats

IF 0.7 Q4 PHARMACOLOGY & PHARMACY
Senjuti Majumder, Hossain Abu Hanif, I. Bulbul, Z. Ahmed, Md. Rajdoula Rafe
{"title":"In-vivo antidiabetic and antidyslipidemic effects of methanolic leaf extract of Combretum indicum in the streptozotocin-induced diabetic rats","authors":"Senjuti Majumder, Hossain Abu Hanif, I. Bulbul, Z. Ahmed, Md. Rajdoula Rafe","doi":"10.4103/epj.epj_16_22","DOIUrl":null,"url":null,"abstract":"Background Combretum indicum (locally known as Basantilata) is a notable medicinal plant belonging to the family Combretaceae. Extracts collected from leaves of this plant have activities including antibacterial, antipyretic, and antidiarrheal activities. Objective This study was designed to evaluate the crude methanolic leaf extract of C. indicum (MLCI) to evaluate its activities in hyperglycemic and dyslipidemic rats. Materials and methods In-vivo antidiabetic and antidyslipidemic activities of the extract were studied in streptozotocin-induced diabetic rat models following the standard protocol established earlier. The rats were randomly divided into groups I–V as normal control, diabetic control, metformin, MLCI 250 mg/kg, and MLCI 500 mg/kg body weight, respectively. Results and conclusion The in-vivo studies indicated concentration-dependent and significant (P<0.05, 0.01, 0.001) reductions of elevated blood glucose, total cholesterol, triglyceride, and low-density lipoprotein-cholesterol levels in the treatment groups compared with diabetes-induced control group. Simultaneously, a significant (P<0.001) rise in high-density lipoprotein-cholesterol level was also observed in the study. The results revealed the advantageous roles of the MLCI in the management of diabetes mellitus.","PeriodicalId":11568,"journal":{"name":"Egyptian Pharmaceutical Journal","volume":"21 1","pages":"312 - 317"},"PeriodicalIF":0.7000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/epj.epj_16_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background Combretum indicum (locally known as Basantilata) is a notable medicinal plant belonging to the family Combretaceae. Extracts collected from leaves of this plant have activities including antibacterial, antipyretic, and antidiarrheal activities. Objective This study was designed to evaluate the crude methanolic leaf extract of C. indicum (MLCI) to evaluate its activities in hyperglycemic and dyslipidemic rats. Materials and methods In-vivo antidiabetic and antidyslipidemic activities of the extract were studied in streptozotocin-induced diabetic rat models following the standard protocol established earlier. The rats were randomly divided into groups I–V as normal control, diabetic control, metformin, MLCI 250 mg/kg, and MLCI 500 mg/kg body weight, respectively. Results and conclusion The in-vivo studies indicated concentration-dependent and significant (P<0.05, 0.01, 0.001) reductions of elevated blood glucose, total cholesterol, triglyceride, and low-density lipoprotein-cholesterol levels in the treatment groups compared with diabetes-induced control group. Simultaneously, a significant (P<0.001) rise in high-density lipoprotein-cholesterol level was also observed in the study. The results revealed the advantageous roles of the MLCI in the management of diabetes mellitus.
紫荆叶甲醇提取物对链脲佐菌素诱导的糖尿病大鼠体内的降糖和降血脂作用
背景印度Combretum indicum(当地称Basantilata)是Combretae科的一种著名药用植物。从这种植物的叶子中提取的提取物具有抗菌、解热和止泻活性。目的评价洋地黄粗甲醇叶提取物(MLCI)对高血糖和血脂异常大鼠的活性。材料和方法按照早期建立的标准方案,在链脲佐菌素诱导的糖尿病大鼠模型中研究提取物的体内抗糖尿病和抗血脂活性。将大鼠随机分为I–V组,分别为正常对照组、糖尿病对照组、二甲双胍组、MLCI 250 mg/kg组和MLCI 500 mg/kg组。结果和结论体内研究表明,与糖尿病诱导的对照组相比,治疗组的血糖、总胆固醇、甘油三酯和低密度脂蛋白胆固醇水平升高呈浓度依赖性且显著降低(P<0.05,0.01,0.001)。同时,研究中还观察到高密度脂蛋白胆固醇水平显著升高(P<0.001)。结果揭示了MLCI在糖尿病治疗中的有利作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Egyptian Pharmaceutical Journal
Egyptian Pharmaceutical Journal PHARMACOLOGY & PHARMACY-
CiteScore
1.10
自引率
0.00%
发文量
37
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信